

Regulus Therapeutics Inc.
Form SC 13G/A
February 13, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*

Regulus Therapeutics Inc.
(Name of Issuer)

COMMON STOCK, \$0.001 PAR VALUE PER SHARE
(Title of Class of Securities)

75915K101
(CUSIP Number)

December 31, 2016
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 75915K101

1. NAMES OF REPORTING PERSONS

Alnylam Pharmaceuticals, Inc.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

SHARES 3,998,621
6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY 0
EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 3,998,621
8. SHARED DISPOSITIVE POWER

WITH

0
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,998,621
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

7.6%⁽¹⁾

12. TYPE OF REPORTING PERSON

CO

- (1) The percentage is calculated based on 52,923,305 shares of the Issuer's common stock outstanding as of October 28, 2016, as disclosed by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 2, 2016.

Page 2 of 5 pages

CUSIP No. 75915K101

Item 1. Issuer

- (a) Name of Issuer:
Regulus Therapeutics Inc. (the **Issuer**)
- (b) Address of Issuer's Principal Executive Offices:
10614 Science Center Dr.

San Diego, CA 92121

Item 2. Filing Person

- (a) (c) Name of Person Filing; Address; Citizenship:
Alnylam Pharmaceuticals, Inc., a Delaware corporation

The address of the principal business office of the reporting person is 300 Third Street, 3rd Floor, Cambridge, MA 02142.

- (d) Title of Class of Securities:
Common stock, \$0.001 par value per share
- (e) CUSIP Number:

75915K101

Item 3. Description of Person Filing

Not applicable.

CUSIP No. 75915K101

Item 4. Ownership.

(a) and (b) Amount beneficially owned; percent of class:

The reporting person directly owns 3,998,621 shares, which represents approximately 7.6%⁽¹⁾ of the outstanding shares of common stock.

(c) Number of shares as to which such person has:

(i) Sole power to vote or direct the vote

3,998,621 shares

(ii) Shared power to vote or to direct the vote

0 shares

(iii) Sole power to dispose or to direct the disposition of

3,998,621 shares

(iv) Shared power to dispose or to direct the disposition of

0 shares

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

- (1) The percentage is calculated based on 52,923,305 shares of the Issuer's common stock outstanding as of October 28, 2016, as disclosed by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 2, 2016.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2017

ALNYLAM PHARMACEUTICALS, INC.

By: /s/ Michael P. Mason
Michael P. Mason
Vice President, Finance and
Treasurer

Page 5 of 5 pages